Sign up to save your podcasts
Or
Share JAMA Oncology : Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
JAMA Oncology : Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
Interview with Robert J. Motzer, MD, author of Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. Hosted by Jack West, MD.
View all episodes
By The JAMA Network
4.9
1212 ratings
Interview with Robert J. Motzer, MD, author of Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. Hosted by Jack West, MD.
More shows like JAMA Network
View all
JAMA Editors' Summary
138 Listeners
Medicine and Science from The BMJ
37 Listeners
NEJM This Week
323 Listeners
Diabetes Core Update
101 Listeners
JAMA Clinical Reviews
500 Listeners
AFP: American Family Physician Podcast
700 Listeners
JAMA Pediatrics Editors' Summary
38 Listeners
Mayo Clinic Talks
290 Listeners
The Curbsiders Internal Medicine Podcast
3,333 Listeners
JAMA Dermatology Author Interviews
17 Listeners
JAMA Internal Medicine Author Interviews
18 Listeners
JAMA Neurology Author Interviews
13 Listeners
JAMA Otolaryngology–Head & Neck Surgery Author Interviews
6 Listeners
JAMA Medical News
88 Listeners
Core IM | Internal Medicine Podcast
1,139 Listeners
JAMAevidence The Rational Clinical Examination
30 Listeners
Annals On Call Podcast
190 Listeners
The Clinical Problem Solvers
514 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
368 Listeners
Cardionerds: A Cardiology Podcast
430 Listeners
JAMAevidence JAMA Guide to Statistics and Methods
19 Listeners
The Curious Clinicians
373 Listeners
NEJM AI Grand Rounds
54 Listeners